



شبكة المعلومات الجامعية

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ





شبكة المعلومات الجامعية



# شبكة المعلومات الجامعية

## التوثيق الالكتروني والميكرو فيلم

# جامعة عين شمس

التوثيق الالكتروني والميكرو فيلم

## قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأفلام قد اعدت دون أية تغيرات



## يجب أن

تحفظ هذه الأفلام بعيداً عن الغبار

في درجة حرارة من 15 – 20 مئوية ورطوبة نسبية من 20-40 %

To be kept away from dust in dry cool place of  
15 – 25c and relative humidity 20-40 %



شبكة المعلومات الجامعية



# بعض الوثائق الأصلية تالفة



شبكة المعلومات الجامعية



بالرسالة صفحات  
لم ترد بالأصل

# **Hormone Replacement Therapy After The Menopause**

An Essay

Submitted in Partial Fulfillment of  
The Master Degree ( M.Sc. ) in  
Obstetrics & Gynecology

*By*

**Ahmed Rezk Aly Elzayat**  
( M.B.B.Ch., Cairo University )

*Supervised By*

**Professor Dr. Mahmoud Ahmed Hussein**  
Professor of Obstetrics & Gynecology  
Faculty of Medicine, Cairo University

**Professor Dr. Hesham Mohamed Al-Ghazaly**  
Professor of Obstetrics & Gynecology  
Faculty of Medicine, Cairo University

**Dr. Ayman Abdelhaleem Marzouk**  
Lecturer of Obstetrics & Gynecology  
Faculty of Medicine, Cairo University

Faculty of Medicine  
Cairo University  
2001

تمت  
هشام محمد الغزالي  
أحمد رضا

B N A E V

1

2

3

4

5

6

7

8

9

10

11

# Acknowledgement

I would like to record my grateful thanks and to express my sincere gratitude and respect to my *Professor Dr. Mahmoud Ahmed Hussein*, Professor of Obstetrics & Gynecology, Faculty of Medicine, Cairo University, for his kind supervision, wise guidance and valuable advice. I was honored and privileged to work with such a great figure in Obstetrics & Gynecology.

I am grateful and sincerely thankful to *Professor Dr. Hesham Mohamed Al-Ghazaly*, Professor of Obstetrics & Gynecology, Faculty of medicine, Cairo University, for his honest assistance, continuous support, and fruitful suggestions throughout the whole work.

I am also deeply grateful to *Dr. Ayman Abdelhaleem Marzouk*, Lecturer of Obstetrics & Gynecology, Faculty of Medicine, Cairo University, for his sincere guidance and constant advice and encouragement.





## List of Abbreviations

|       |                                          |
|-------|------------------------------------------|
| ACTH: | <i>Adrenocorticotrophic hormone</i>      |
| CBG:  | <i>corticostetroid-binding globulin</i>  |
| CHD:  | <i>Coronary heart disease</i>            |
| DES:  | <i>Diethyl stilbesterol</i>              |
| DEXA: | <i>Dual energy x – ray absorbiometry</i> |
| DNA:  | <i>Deoxy ribonucleic acid</i>            |
| DPA:  | <i>Dual photon absorbiometry</i>         |
| DUB:  | <i>Dysfunctional uterine bleeding</i>    |
| E1:   | <i>Estrone</i>                           |
| E2:   | <i>Estradiol</i>                         |
| E3:   | <i>Estriol</i>                           |
| EE2:  | <i>Ethinyl estradiol</i>                 |
| ERT:  | <i>Estrogen replacement therapy</i>      |
| Es:   | <i>Synthetic estrogens</i>               |
| FSH:  | <i>Follicular stimulating hormone</i>    |
| HDL:  | <i>High-density lipoprotein</i>          |
| HRT:  | <i>Hormone replacement therapy</i>       |
| IQ:   | <i>Intelligent quotient</i>              |
| IUD:  | <i>Intrauterine device</i>               |
| LDL:  | <i>Low density lipoprotein</i>           |
| LH:   | <i>Leutenizing hormone</i>               |
| MPA:  | <i>Medroxy progesterone acetate</i>      |

|       |                                                       |
|-------|-------------------------------------------------------|
| OCs:  | <i>Oral contraceptives</i>                            |
| PEPI: | <i>Postmenopausal estrogen progestin intervention</i> |
| RNA:  | <i>Ribonucleic acid</i>                               |
| SD:   | <i>Standard deviation</i>                             |
| SHBG: | <i>Sex hormone binding globulin</i>                   |
| TSH:  | <i>Thyroid stimulating hormone</i>                    |
| VLDL: | <i>Very low-density lipoprotein</i>                   |

## Table of contents

|                                                                            |           |
|----------------------------------------------------------------------------|-----------|
| <b>Introduction .....</b>                                                  | <b>1</b>  |
| <b>Aim of the work .....</b>                                               | <b>2</b>  |
| <br><b><u>Chapter I</u></b>                                                |           |
| <b><u>Menopause, Physiological &amp; Clinical Considerations .....</u></b> | <b>3</b>  |
| <b>Factors influencing the age at menopause .....</b>                      | <b>3</b>  |
| 1 - Age at menarche .....                                                  | 3         |
| 2 - Smoking .....                                                          | 4         |
| 3 - Marital status .....                                                   | 6         |
| 4 - Occupation .....                                                       | 6         |
| 5 - Menstrual Character .....                                              | 7         |
| 6 - Parity .....                                                           | 8         |
| 7 - Contraceptives and exogenous hormone .....                             | 9         |
| 8 - Diet habits and Nutritional status .....                               | 11        |
| 9 - Race and Geographical area .....                                       | 11        |
| 10 - Obesity and Age at menopause .....                                    | 12        |
| <b>Physiological Changes At Climacteric .....</b>                          | <b>13</b> |
| - Endocrine changes during and after the climacteric.....                  | 13        |
| <b>Patho-Physiology Of Climacteric Symptoms .....</b>                      | <b>17</b> |
| 1 ) Altered menstrual function .....                                       | 18        |
| 2 ) Vasomotor instability .....                                            | 18        |
| 3 ) Psychological changes .....                                            | 19        |
| 4 ) Atrophy of the Genito-urinary system .....                             | 21        |
| A - Vulva .....                                                            | 21        |
| B - Vagina .....                                                           | 23        |
| C - Urinary tract .....                                                    | 24        |
| 5 ) Anal sphincter .....                                                   | 25        |
| 6 ) Skin changes .....                                                     | 25        |
| 7 ) Breast changes .....                                                   | 26        |
| 8 ) Pituitary changes .....                                                | 27        |

## Table of contents ( Cont. )

|                                                |    |
|------------------------------------------------|----|
| 9 ) Muscles & Joint changes .....              | 28 |
| 10 ) Fertility .....                           | 28 |
| 11 ) Other body organs changes .....           | 28 |
| A – Gastro-intestinal changes .....            | 28 |
| B – Blood coagulation changes .....            | 29 |
| C – Blood pressure changes .....               | 29 |
| 12 ) Bone changes or osteoporosis .....        | 31 |
| Incidence .....                                | 31 |
| Risk factors .....                             | 32 |
| Menopausal bone loss .....                     | 33 |
| Age related bone loss .....                    | 34 |
| Methods of assessment of skeleton .....        | 35 |
| 13 ) Cardiovascular changes .....              | 36 |
| 14 ) Serum lipids & Lipoproteins changes ..... | 38 |
| Sexuality & Menopause .....                    | 40 |

## Chapter II

|                                                    |    |
|----------------------------------------------------|----|
| <u>Hormone Replacement Therapy</u> .....           | 43 |
| <u>Pharmacology Of Hormones</u> .....              | 43 |
| I – Estrogen .....                                 | 43 |
| Estrogens in clinical use .....                    | 44 |
| ⇒ Conjugated steroidal estrogens .....             | 44 |
| * Estrones .....                                   | 45 |
| * Estradiols .....                                 | 45 |
| * Estriols .....                                   | 45 |
| ⇒ Non conjugated steroidal estrogens .....         | 45 |
| ⇒ Synthetic estrogen analogues (non-steroid) ..... | 45 |
| ⇒ Naphthalene derivatives .....                    | 45 |
| II – Progesterone .....                            | 46 |
| 1 ) 19-norethisterone derivatives .....            | 46 |
| 2 ) 17-hydroxy-progesterone derivatives .....      | 47 |
| 3 ) Natural human progesterone .....               | 47 |

## Table of contents ( Cont.)

|                                                                            |           |
|----------------------------------------------------------------------------|-----------|
| <b>Routes of Estrogen Replacement Therapy .....</b>                        | <b>47</b> |
| I – Oral Route .....                                                       | 47        |
| II – Vaginal Route .....                                                   | 54        |
| III – Transdermal administration .....                                     | 56        |
| IV – Estradiol implants .....                                              | 58        |
| V – Percutaneous Estrogen .....                                            | 59        |
| VI – Sublingual, Intranasal & Injectable Estrogens .....                   | 59        |
| - The narrow therapeutic window .....                                      | 60        |
| <b>Clinical endocrinology .....</b>                                        | <b>61</b> |
| <b>Benefits Of Hormone Replacement Therapy .....</b>                       | <b>66</b> |
| <b>Selection of patients for treatment .....</b>                           | <b>66</b> |
| <b>The peri-menopausal transition years .....</b>                          | <b>66</b> |
| <b>The early post-menopause .....</b>                                      | <b>67</b> |
| <b>The late post-menopause .....</b>                                       | <b>67</b> |
| Estrogen and hot flush .....                                               | 68        |
| Estrogen and genito-urinary system .....                                   | 69        |
| Estrogen and psychologic changes .....                                     | 71        |
| Estrogen and osteoporosis .....                                            | 72        |
| Estrogen and cardiovascular diseases .....                                 | 75        |
| Estrogen and skin changes .....                                            | 78        |
| <b>Should very old women be started on hormone therapy? .....</b>          | <b>78</b> |
| <b>How long should post-menopausal hormone therapy be continued? .....</b> | <b>79</b> |
| <b>Risk Factors Of Hormone Replacement Therapy .....</b>                   | <b>80</b> |
| I – Hepatic effects .....                                                  | 80        |
| II – Endometrial cancer .....                                              | 81        |
| III – Cancer breast .....                                                  | 84        |
| IV – Hypertension .....                                                    | 87        |
| V – Thrombo-embolic disease .....                                          | 88        |
| VI – Cancer cervix .....                                                   | 89        |
| VII – Glucose tolerance .....                                              | 90        |
| VIII – Cholelithiasis .....                                                | 91        |
| IX – Side effects .....                                                    | 91        |

## Table of contents ( Cont. )

|                                                                               |     |
|-------------------------------------------------------------------------------|-----|
| Balancing The Benefits & Risks Of Estrogen Therapy .....                      | 92  |
| <i>Cautions &amp; Contraindications To Estrogen Replacement Therapy</i> ..... | 94  |
| A – Absolute contraindications to ERT .....                                   | 94  |
| B – Relative contraindications .....                                          | 94  |
| <i>The Current Concept For Menopausal Hormone Replacement Therapy</i> .....   | 94  |
| Managing bleeding during postmenopausal HRT .....                             | 96  |
| Choice and duration of progestin.....                                         | 100 |
| The progestin intrauterine device.....                                        | 101 |
| <i>Could progestin be administered to hysterectomized women?</i> .....        | 101 |
| * Tibolone (Livial) .....                                                     | 104 |
| * Endometrial ablation resection .....                                        | 105 |
| <br><i>Summary</i> .....                                                      | 107 |
| <br><i>References</i> .....                                                   | 112 |
| <br><i>Arabic Summary</i> .....                                               | 157 |